Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | IV daratumumab in R/R myeloma: bodyweight analysis

Maria Victoria-Mateos • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Daratumumab
COLUMBA

Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the Phase III COLUMBA (NCT03277105) study evaluating subcutaneous intravenous (IV) daratumumab in relapsed/refractory (R/R) multiple myeloma patients, specifically discussed is the results of the bodyweight subgroup analysis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maria Victoria-Mateos

CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma 1:53
CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma 2:17
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma 2:16
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial 1:46
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial
Maria Victoria-Mateos • 1 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals